Clinical trial · Observational
Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
NCT04922541CI-TRIAL-00052202unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Plaque, Atherosclerotic | — | UNRESOLVED | — |
| Programmed Cell Death Protein 1 Inhibitor | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PD-1 inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Sizes of plaque areas at the same locations on artery ultrasound
- timeFrame
- at least of 3 months after the first dosage of anti-PD-1 mAbs
- description
- Comparison of the sizes of plaque areas at the same locations on artery ultrasound before and after anti-PD-1 mAbs treatments.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. The age is 18-90 years old (including 18 and 90 years old); 2. The subjects knew about the experiment and signed the informed consent voluntarily; 3. The subjects complicated with tumor diseases and atherosclerotic plaques; 4. The subjects received regular PD-1 inhibitor treatment; 5. The subjects had ultrasound images of atherosclerotic plaques before- and after- or during PD-1 blockade treatment at the two different timepoints; 6. The subjects received regular treatments of PD-1 inhibitor during the two timepoints of artery ultrasound examinations; 7. The subjects who had ultrasound images before the initiation of first-dose PD-1 inhibitor, the interval between these two timepoints should be restricted within 1 month; 8. The subjects who had ultrasound images after 3 months of PD-1 inhibitor treatment. Exclusion Criteria: 1. Subjects stop receiving PD-1 inhibitor treatments during follow-up; 2. Subjects are reluctant to continue to be involved in this study; Known pregnant and lactating women; 3. Plaque areas can not be calculated because of the quality of ultrasound image; 4. Other situations that the researchers judged were not suitable for inclusion.
References
Publications (0)
Data not yet available
No reference posted for this study.